Viva Biotech HoldingsFRA:VB0 43 PS Ratio is 1.37 as of Jul. 01, 2026, which is 42% below its 10-year median of 2.36. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 934 Biotechnology companies, Viva Biotech Holdings ranks better than 89.4% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Viva Biotech Holdings's share price is €0.123.
Viva Biotech Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.09. Hence, Viva Biotech Holdings's PS Ratio for today is 1.37.
Good Sign:
Viva Biotech Holdings stock PS Ratio (=1.37) is close to 1-year low of 1.37.
The historical rank and industry rank for Viva Biotech Holdings's PS Ratio or its related term are showing as below:
FRA:VB0'
s PS Ratio Range Over the Past 10 Years
Min: 0.36 Med: 2.36 Max: 43.31
Current: 1.29
During the past 10 years, Viva Biotech Holdings's highest PS Ratio was 43.31. The lowest was 0.36. And the median was 2.36.
FRA:VB0's PS Ratio is ranked better than 89.4% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs FRA:VB0: 1.29
Viva Biotech Holdings revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Viva Biotech Holdings was 10.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -16.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.90% per year.
During the past 10 years, Viva Biotech Holdings's highest 3-Year average Revenue per Share Growth Rate was 101.80% per year. The lowest was -17.30% per year. And the median was 49.80% per year.
Back to Basics: PS Ratio
Viva Biotech Holdings (FRA:VB0) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Viva Biotech Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Viva Biotech Holdings's Share Price of today is €0.123.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Viva Biotech Holdings (FRA:VB0) has a PS Ratio of 1.37 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Viva Biotech Holdings and its competitors. This is 42% below median its historical median of 2.36. Over the past decade, Viva Biotech Holdings' PS Ratio has ranged from 0.36 to 43.31. According to the industry distribution chart, Viva Biotech Holdings ranks #99 out of 934 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Viva Biotech Holdings' PS Ratio too high?
Viva Biotech Holdings' current PS Ratio of 1.37 is 42% below median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 43.31. The Biotechnology industry median PS Ratio is 9.52. Viva Biotech Holdings' value of 1.37 is 85.6% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #99 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #99 out of 934 companies for PS Ratio. This places Viva Biotech Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.52. Viva Biotech Holdings' value of 1.37 is 85.6% below this benchmark. Historically, Viva Biotech Holdings' own PS Ratio has ranged from 0.36 to 43.31 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 9.52, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current PS Ratio of 1.37 is 85.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current PS Ratio is 1.37, which is 42% below median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.12 — trading 53.8% above its estimated fair value. The current PS Ratio is 1.37, which is 42% below median its 10-year median of 2.36 and 85.6% below the Biotechnology industry median of 9.52. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current PS Ratio is 1.37 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.12 is trading 53.8% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
PS Ratio: 1.37 (42% below median its 10-year median of 2.36)
GF Value™: €0.08 vs. price of €0.12 (53.8% above fair value)
Industry Position: 85.6% below the Biotechnology median (#99 of 934)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score
Get the complete analysis for FRA:VB0
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
